Finance

Lists
87S:FRA
Roivant Sciences Ltd
€28.88
-0.17%
(-0.050) 1D
Sep 4, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 87S...
Open
€29.21
High
€29.23
Low
€28.88
Mkt. cap
25.23B
Avg. vol.
0.00
Volume
0.00
52-wk high
€32.21
52-wk low
€10.40
No. of employees
721
Open
€29.21
High
€29.23
Low
€28.88
Mkt. cap
25.23B
Avg. vol.
0.00
Volume
0.00
52-wk high
€32.21
52-wk low
€10.40
No. of employees
721
News stories
From web sources and news partners
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd
CEOMatt Gline
Employees721
FoundedApr 7, 2014
Headquarters-
SectorBiotechnology
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.57M
2.00M
2.52M
1.44M
Cost of goods sold
164.18M
166.08M
199.26M
202.30M
Cost of revenue
164.18M
166.08M
199.26M
202.30M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
129.52M
175.05M
173.07M
165.53M
Operating expense
129.52M
175.05M
173.07M
165.53M
Total operating expenses
293.70M
341.13M
372.33M
367.83M
Operating income
-292.13M
-339.14M
-369.81M
-366.38M
Other non operating income
-26.65M
-16.07M
12.57M
-2.93M
EBT including unusual items
-159.04M
-290.37M
454.10M
-294.56M
EBT excluding unusual items
-273.44M
-311.94M
-316.06M
-331.59M
Income tax expense
7.00M
23.33M
98.35M
-3.96M
Effective tax rate
-4.40%
-8.04%
21.66%
1.34%
Other operating expenses
-
-
-
-
Net income
-113.52M
-265.89M
302.99M
-189.84M
Net profit margin
-7,225.91%
-13,301.20%
12,023.57%
-13,164.84%
Earnings per share
-0.28
-0.24
-0.32
-0.34
Interest and investment income
45.34M
43.27M
41.18M
36.92M
Interest expense
-
-
-
-
Net interest expenses
45.34M
43.27M
41.18M
36.92M
Depreciation and amortization charges
-
-
-
-
EBITDA
-291.21M
-338.44M
-369.17M
-365.78M
Gain or loss from assets sale
-
-
-11.03M
-
AI content may include mistakes. Learn more
Google apps